Over a month ago |
On The Fly
|
What has Wall Street been… ShowHide Related Items >><< - 12/15/22
- Aziyo Biologics announces funding of additional $4M term loan
- 10/10/22
- SWK Holdings unit receives $5M milestone payment from Cara Therapeutics
- 10/03/22
- SWK Holdings names Yvette Heinrichson as CFO, succeeding Charles Jacobson
- 09/01/22
- SWK Holdings appoints Jody Staggs as Interim CEO
- 12/21/22
- Nike Training Club on Netflix launches December 30
- 12/14/22
- Verizon announces early access to +play beta
- 12/06/22
- Netflix CEO Sarandos sees multiple ad tiers over time
- 12/01/22
- Enthusiast Gaming, Netflix enter content partnership for Geeked: Toon-in
- 12/05/22
- Ideaya Biosciences granted fast track designation for darovasertib
- 11/28/22
- Ideaya Biosciences announces Darrin Beaupre as chief medical officer
- 10/18/22
- Ideaya Biosciences provides update on IDE397 clinical program
- 10/17/22
- Zentalis appoints Lackner as Chief Translational Officer
- 12/07/22
- Generac acquires equity stake in WATT Fuel Cell
- 11/29/22
- Generac falls -4.6%
- 11/09/22
- Generac announces passing of founder Robert Kern
- 10/19/22
- Generac falls -21.9%
- 11/22/22
- Shift4 Payments falls -8.5%
- 11/07/22
- Shift4 Payments rises 10.6%
- 08/04/22
- Shift4 Payments rises 14.0%
- 08/04/22
- Shift4 Payments appoints Nancy Disman CFO
- 12/29/22 CFRA
- Netflix upgraded to Buy from Sell at CFRA
- 12/22/22 Needham
- Netflix 2023 estimates cut at Needham
- 12/20/22 Oppenheimer
- Oppenheimer reiterates bullish stance on Netflix's ad tier driving sub growth
- 12/19/22 Morgan Stanley
- Netflix price target raised to $275 from $250 at Morgan Stanley
- 12/29/22 Piper Sandler
- Shift4 Payments assumed with an Overweight at Piper Sandler
- 11/16/22 Susquehanna
- Susquehanna sees Twitter payments potential for Shift4 Payments
- 11/08/22 Truist
- Shift4 Payments price target lowered to $55 from $65 at Truist
- 11/07/22 Truist
- Shift4 Payments price target lowered to $55 from $65 at Truist
- 12/28/22 Lake Street
- SWK Holdings assumed with a Buy at Lake Street
- 04/18/22 Lake Street
- SWK Holdings initiated with a Buy at Lake Street
- 12/28/22 Northland
- Generac named a 'top pick for 2023' at Northland
- 12/28/22 Janney Montgomery Scott
- Janney starts Generac with a Buy, sees core HSB headwinds priced in
- 12/28/22 Janney Montgomery Scott
- Generac initiated with a Buy at Janney Montgomery Scott
- 12/20/22 Baird
- Generac downgraded to Neutral from Outperform at Baird
- 12/28/22 Capital One
- Capital One starts Ideaya Biosciences at Overweight with $29 price target
- 12/28/22 Capital One
- Ideaya Biosciences initiated with an Overweight at Capital One
- 11/18/22 Baird
- Ideaya Biosciences price target raised to $24 from $18 at Baird
- 10/27/22 Citi
- Ideaya Biosciences initiated with a Buy at Citi
- 11/09/22
- SWK Holdings reports Q3 GAAP EPS 51c vs. 17c a year ago
- 10/18/22
- Netflix sees Q4 EPS 36c, consensus $1.12
- 10/18/22
- Netflix reports Q3 EPS $3.10, consensus $2.13
- 10/18/22
- Notable companies reporting after market close
- 07/19/22
- Netflix sees Q3 EPS $2.14, consensus $2.77
- 11/08/22
- Ideaya Biosciences reports Q3 EPS 4c, consensus (62c)
- 08/15/22
- Ideaya Biosciences reports Q2 EPS (57c), consensus (52c)
- 11/02/22
- Generac sees FY22 net revenue growth 22%-24%, consensus $4.7B
- 11/02/22
- Generac reports Q3 adjusted EPS $1.75, consensus $1.83
- 10/19/22
- Generac sees Q3 adjusted EPS $1.75, consensus $3.21
- 08/03/22
- Generac backs FY22 revenue growth view 36%-40%, consensus $5.17B
- 11/07/22
- Shift4 Payments sees FY22 gross revenue $1.95B-$2B, consensus $2.01B
- 11/07/22
- Shift4 Payments reports Q3 adjusted EPS 44c, consensus 43c
- 08/04/22
- Shift4 Payments backs FY22 revenue view $1.9B-$2B, consensus $1.99B
- 08/04/22
- Shift4 Payments reports Q2 EPS 33c, consensus 24c
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - $108.35 /
-1.8401 (-1.67%) - 12/14/22
- Exxon Mobil begins operations at large-scale advanced recycling facility
- 12/08/22
- Exxon Mobil allocates $17B to emission reductions efforts
- 12/08/22
- Exxon Mobil: Upstream earnings potential expected to double by 2027 versus 2019
- 12/08/22
- Exxon Mobil expects earnings, cash flow to double by 2027 vs. 2019
- 12/27/22
- Cathie Wood's ARK Investment bought 25.1K shares of Tesla today
- 12/27/22
- Tesla debuts Wireless Charging Platform, 'inspired' by Cybertruck design
- 12/27/22
- Tesla down 5% in pre-market following reports of suspended Shanghai output
- 12/22/22
- Tesla up 2% afterhours as CEO Musk says he will pause his share sales
- 12/16/22
- Tilray announces limited-edition, premium craft flower series by RIFF
- 12/06/22
- Good Supply cannabis brand launches 'Peppermint Phatty'
- 12/02/22
- White House announces signing of medical marijuana research expansion act
- 11/18/22
- Tilray launches a new platform to connect women with free cannabis resources
- 12/28/22
- TG Therapeutics up 33% after receiving FDA approval for Briumvi
- 12/28/22
- TG Therapeutics trading resumes
- 12/28/22
- TG Therapeutics to resume trading at 2:20 p.m. ET
- 12/28/22
- TG Therapeutics announces FDA approval of Briumvi
- 12/12/22
- Rivian Automotive pauses plans to produce electric commercial vans in Europe
- 12/06/22
- Vietnam-based EV maker VinFast plans for U.S. IPO
- 12/05/22
- Rivian Automotive enters wind energy deal with Apex Clean Energy
- 11/14/22
- Soros Fund Management buys Sierra Wireless, exits Kinder Morgan in Q3
- 12/05/22
- Riot Blockchain announces November 2022 production, operations update
- 11/21/22
- Crypto names down in pre-market as bitcoin falls to one-week low
- 11/11/22
- FTX commences Chapter 11 proceedings, Bankman-Fried resigns
- 11/10/22
- FTX US says trading may be halted 'in a few days'
- 12/28/22
- Meta Materials to showcase global technology collaborations at CES 2023
- 12/15/22
- Meta Materials completes distribution of Next Bridge Hydrocarbon shares
- 12/07/22
- Meta Materials says FINRA processed corporate action for exchange of Series A
- 12/06/22
- Meta Materials announces results of Annual Meeting of Shareholders
KALA Kala Pharmaceuticals - $12.47 /
+8.57 (+219.74%) - 12/27/22
- Kala Pharmaceuticals jumps 64% after FDA accepted application for KPI-012
- 12/27/22
- Kala Pharmaceuticals announces FDA acceptance of IND application for KPI-012
- 11/28/22
- Kala announces submission of IND for KPI-012 for PCED treatment
- 11/01/22
- Kala Pharmaceuticals appoints Farid to board of directors
- 12/08/22
- Jounce Therapeutics presents INNATE Phase 1, SELECT trial data
- 11/10/22
- Jounce Therapeutics expects cash to fund operating expenses into 1Q24
- 11/02/22
- Jounce earns clinical milestone payment under agreement with Gilead
- 12/05/22
- Ideaya Biosciences granted fast track designation for darovasertib
- 11/28/22
- Ideaya Biosciences announces Darrin Beaupre as chief medical officer
- 10/18/22
- Ideaya Biosciences provides update on IDE397 clinical program
- 10/17/22
- Zentalis appoints Lackner as Chief Translational Officer
- 12/07/22
- Generac acquires equity stake in WATT Fuel Cell
- 11/29/22
- Generac falls -4.6%
- 11/09/22
- Generac announces passing of founder Robert Kern
- 10/19/22
- Generac falls -21.9%
- 12/27/22
- Gilead to buy remaining rights for GS-1811 from Jounce Therapeutics for $67M
- 12/22/22
- Kite says Yescarta now approved in Japan for initial treatment
- 12/22/22
- Gilead announces Sunlenca granted FDA approval in multidrug resistant HIV
- 12/20/22
- Kite to acquire Tmunity, terms undisclosed
- 12/28/22
- Disney says 'Avatar: The Way of Water' tops $1B in global sales
- 12/27/22
- Imax crosses $100M in global box office with 'Avatar: The Way of Water'
- 12/26/22
- Fly Intel: Top five weekend stock stories
- 12/19/22
- Epic Games to pay $520M to settle FTC allegations
- 12/28/22
- Voip-Pal.com announces PTAB denies institution of four IPR petitions
- 12/22/22
- Stingray Group launches TV channels on Amazon Freevee, Samsung TV Plus
- 12/20/22
- EU accepts Amazon commitments, ending antitrust investigations
- 12/19/22
- Amazon Web Services awarded $723.88M Navy BPA
- 12/28/22
- Akoustis receives first design win in 5G mobile from Tier-1 RF component company
- 12/21/22
- Akoustis completes qualification of first wafer-level-packages for 5G mobile
- 11/21/22
- Akoustis joins Wi-Fi NOW industry association as Official RF Filter Partner
- 10/26/22
- Akoustis receives three new Wi-Fi 6E design wins
- 12/01/22
- Akili Interactive appoints Scott Kollins as chief medical officer
- 08/26/22
- Temasek Holdings reports 13.5% passive stake in Akili Interactive
- 08/19/22
- Akili to start trading on Nasdaq on August 22
- 12/28/22 Northland
- Generac named a 'top pick for 2023' at Northland
- 12/28/22 Janney Montgomery Scott
- Janney starts Generac with a Buy, sees core HSB headwinds priced in
- 12/28/22 Janney Montgomery Scott
- Generac initiated with a Buy at Janney Montgomery Scott
- 12/20/22 Baird
- Generac downgraded to Neutral from Outperform at Baird
- 12/28/22 Morgan Stanley
- Tesla price target lowered to $250 from $330 at Morgan Stanley
- 12/28/22 Wedbush
- Wedbush lays out what needs to happen for Tesla shares to bottom
- 12/28/22 Baird
- Baird cuts Tesla target to $252, keeps as 'Best Idea' in 2023
- 12/23/22 Wedbush
- Tesla price target lowered to $175 from $250 at Wedbush
- 12/28/22 Cantor Fitzgerald
- Riot, Rivian among Cantor's top technology picks for 2023
- 12/15/22 Northland
- Riot Blockchain price target lowered to $10 from $12 at Northland
- 12/15/22 DA Davidson
- Riot Blockchain price target lowered to $10 from $12 at DA Davidson
- 11/23/22 H.C. Wainwright
- Riot Blockchain assumed with a Buy at H.C. Wainwright
- 12/20/22 Cantor Fitzgerald
- Rivian Automotive initiated with an Overweight at Cantor Fitzgerald
- 12/20/22 Mizuho
- Rivian Automotive price target lowered to $50 from $58 at Mizuho
- 12/13/22 Canaccord
- Rivian Automotive production pause preserves capital, says Canaccord
- 12/28/22 Morgan Stanley
- Akili initiated with an Equal Weight at Morgan Stanley
- 11/18/22 BofA
- Akili Interactive initiated with a Neutral at BofA with spending needed to scale
- 11/18/22 BofA
- Akili Interactive initiated with a Neutral at BofA
- 10/25/22 Credit Suisse
- Akili Interactive initiated with an Outperform at Credit Suisse
- 12/28/22 Capital One
- Capital One starts Ideaya Biosciences at Overweight with $29 price target
- 12/28/22 Capital One
- Ideaya Biosciences initiated with an Overweight at Capital One
- 11/18/22 Baird
- Ideaya Biosciences price target raised to $24 from $18 at Baird
- 10/27/22 Citi
- Ideaya Biosciences initiated with a Buy at Citi
- 12/22/22 Piper Sandler
- Gilead's Sunlenca could expand into broader HIV, says Piper Sandler
- 12/13/22 BofA
- Gilead resumed with a Neutral at BofA
- 12/12/22 Needham
- Arcellx price target raised to $35 from $31 at Needham
- 12/09/22 Piper Sandler
- Gilead price target raised to $104 from $96 at Piper Sandler
- 11/11/22 Raymond James
- Raymond James downgrades Jounce to Outperform on ILT inhibitor data
- 11/10/22 Raymond James
- Jounce Therapeutics downgraded to Outperform from Strong Buy at Raymond James
- 08/30/22 Piper Sandler
- Jounce Therapeutics price target lowered to $6 from $9 at Piper Sandler
- 08/05/22 H.C. Wainwright
- Jounce Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
- $108.35 /
-1.8401 (-1.67%) - 12/19/22 Piper Sandler
- Exxon Mobil price target lowered to $127 from $131 at Piper Sandler
- 11/22/22 Citi
- Exxon Mobil price target raised to $110 from $98 at Citi
- 11/11/22 Piper Sandler
- Exxon Mobil price target raised to $131 from $113 at Piper Sandler
- 11/01/22 Exane BNP Paribas
- Exxon Mobil upgraded to Neutral from Underperform at Exane BNP Paribas
- 12/23/22 Citi
- Sunday Ticket could accelerate adoption of subscriptions at YouTube, says Citi
- 12/19/22 Evercore ISI
- Amazon.com price target lowered to $150 from $170 at Evercore ISI
- 12/16/22 JPMorgan
- JPMorgan cuts Amazon target, says sentiment at multi-year low
- 12/12/22 Wells Fargo
- Amazon GMV beginning to re-accelerate as softlines comps slow, says Wells Fargo
- 12/20/22 Wells Fargo
- Wells says Disney spinning ESPN/ABC 'a reasonably probable event' for late 2023
- 12/12/22 Morgan Stanley
- Disney price target lowered to $115 from $125 at Morgan Stanley
- 11/30/22 Atlantic Equities
- Atlantic Equities sees 'no easy fix' for Iger at Disney
- 11/22/22 Tigress Financial
- Disney price target lowered to $177 from $229 at Tigress Financial
- 11/14/22 Oppenheimer
- Akoustis price target lowered to $7 from $8 at Oppenheimer
- 11/14/22 Piper Sandler
- Akoustis remains on track to continue expanding solutions, says Piper Sandler
- 09/13/22 Piper Sandler
- Akoustis price target lowered to $5 from $7 at Piper Sandler
- 05/17/22 Piper Sandler
- Piper moves to 'more positive stance' on semiconductor stocks
KALA Kala Pharmaceuticals - $12.47 /
+8.57 (+219.74%) - 11/09/22 Wedbush
- Kala Pharmaceuticals price target raised to $47 from $3 at Wedbush
- 05/24/22 H.C. Wainwright
- Kala Pharmaceuticals price target lowered to $4 from $5 at H.C. Wainwright
- 05/17/22 H.C. Wainwright
- Kala Pharmaceuticals price target lowered to $5 from $6 at H.C. Wainwright
- 03/30/22 Northland
- Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
- 12/28/22 Piper Sandler
- Tilray estimates lowered on softer beer sales at Piper Sandler
- 11/09/22 Bernstein
- Two more states legalize cannabis, $3B added to TAM, says Bernstein
- 11/01/22 Bernstein
- Tilray initiated with Market Perform, $3.90 target at Bernstein
- 11/01/22 Bernstein
- Tilray initiated with a Market Perform at Bernstein
- 12/29/22 JPMorgan
- TG shares under-reflect Briumvi potential, says JPMorgan
- 12/29/22 H.C. Wainwright
- TG Therapeutics price target raised to $24 from $19 at H.C. Wainwright
- 12/29/22 BofA
- BofA sees 'bearish setup' for TG Therapeutics into Briumvi launch
- 12/28/22 Cantor Fitzgerald
- Label for TG Therapeutics' Briumvi slightly better than expected, says Cantor
- $108.35 /
-1.8401 (-1.67%) - 10/28/22
- Exxon Mobil reports Q3 adjusted EPS $4.45, consensus $3.79
- 10/27/22
- Notable companies reporting before tomorrow's open
- 07/29/22
- Exxon Mobil reports Q2 adjusted EPS $4.14, consensus $3.74
- 10/19/22
- Tesla reports Q3 EPS $1.05, consensus 99c
- 10/19/22
- Notable companies reporting after market close
- 07/20/22
- Tesla reports Q2 EPS $2.27, consensus $1.85
- 07/20/22
- Notable companies reporting after market close
- 10/07/22
- Tilray reports Q1 adjusted EPS (8c) vs. (13c) last year
- 07/28/22
- Tilray reports Q4 EPS (90c) vs. 38c last year
- 11/10/22
- TG Therapeutics reports Q3 EPS (26c), consensus (39c)
- 08/08/22
- TG Therapeutics reports Q2 EPS (30c), consensus (51c)
- 11/09/22
- Rivian Automotive reports Q3 adjusted EPS ($1.57), consensus ($1.82)
- 11/09/22
- Notable companies reporting after market close
- 10/27/22
- Amazon reports Q3 EPS 28c with Rivian gain, consensus 21c
- 08/11/22
- Rivian Automotive reports Q2 EPS ($1.89), consensus ($1.67)
- 08/15/22
- Riot Blockchain reports Q2 adjusted EPS (50c), consensus 3c
KALA Kala Pharmaceuticals - $12.47 /
+8.57 (+219.74%) - 11/08/22
- Kala Pharmaceuticals reports Q3 EPS $19.25 vs ($21.41) last year
- 08/11/22
- Kala Pharmaceuticals reports Q2 EPS (38c) vs. (57c) last year
- 11/10/22
- Jounce Therapeutics reports Q3 EPS (60c), consensus (64c)
- 08/04/22
- Jounce Therapeutics reports Q2 EPS (65c), consensus (68c)
- 11/08/22
- Ideaya Biosciences reports Q3 EPS 4c, consensus (62c)
- 08/15/22
- Ideaya Biosciences reports Q2 EPS (57c), consensus (52c)
- 11/02/22
- Generac sees FY22 net revenue growth 22%-24%, consensus $4.7B
- 11/02/22
- Generac reports Q3 adjusted EPS $1.75, consensus $1.83
- 10/19/22
- Generac sees Q3 adjusted EPS $1.75, consensus $3.21
- 08/03/22
- Generac backs FY22 revenue growth view 36%-40%, consensus $5.17B
- 12/20/22
- Gilead expects Tmunity acquisition to reduce FY23 EPS by 18c-22c
- 10/27/22
- Gilead raises FY22 adjusted EPS view to $6.95-$7.15 from $6.35-$6.75
- 10/27/22
- Gilead Sciences reports Q3 adjusted EPS $1.90, consensus $1.43
- 10/27/22
- Notable companies reporting after market close
- 11/08/22
- Disney CFO sees FY23 cash content spend in low-$30B range
- 11/08/22
- Disney reports Q4 EPS ex-items 30c, consensus 57c
- 11/08/22
- Notable companies reporting after market close
- 08/10/22
- Disney reports Q3 EPS ex-items $1.09, consensus $1.00
- 10/27/22
- Amazon sees Q4 revenue $140B-$148B, consensus $155.15B
- 07/28/22
- Amazon reports Q2 AWS net sales $19.73B vs. $14.81B a year ago
- 11/14/22
- Akoustis reports Q4 adjusted EPS (28c), consensus (20c)
- 09/12/22
- Akoustis reports Q4 non-GAAP EPS (26c), consensus (19c)
- 11/10/22
- Akili Interactive reports Q3 net loss ($18.5M) vs ($16.4M) last year
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 12/14/22
- Exxon Mobil begins operations at large-scale advanced recycling facility
- 12/08/22
- Exxon Mobil allocates $17B to emission reductions efforts
- 12/08/22
- Exxon Mobil: Upstream earnings potential expected to double by 2027 versus 2019
- 12/08/22
- Exxon Mobil expects earnings, cash flow to double by 2027 vs. 2019
- 12/27/22
- Cathie Wood's ARK Investment bought 25.1K shares of Tesla today
- 12/27/22
- Tesla debuts Wireless Charging Platform, 'inspired' by Cybertruck design
- 12/27/22
- Tesla down 5% in pre-market following reports of suspended Shanghai output
- 12/22/22
- Tesla up 2% afterhours as CEO Musk says he will pause his share sales
- 12/16/22
- Tilray announces limited-edition, premium craft flower series by RIFF
- 12/06/22
- Good Supply cannabis brand launches 'Peppermint Phatty'
- 12/02/22
- White House announces signing of medical marijuana research expansion act
- 11/18/22
- Tilray launches a new platform to connect women with free cannabis resources
- 12/12/22
- Rivian Automotive pauses plans to produce electric commercial vans in Europe
- 12/06/22
- Vietnam-based EV maker VinFast plans for U.S. IPO
- 12/05/22
- Rivian Automotive enters wind energy deal with Apex Clean Energy
- 11/14/22
- Soros Fund Management buys Sierra Wireless, exits Kinder Morgan in Q3
- 12/05/22
- Riot Blockchain announces November 2022 production, operations update
- 11/21/22
- Crypto names down in pre-market as bitcoin falls to one-week low
- 11/11/22
- FTX commences Chapter 11 proceedings, Bankman-Fried resigns
- 11/10/22
- FTX US says trading may be halted 'in a few days'
- 12/28/22
- Pfizer announces FDA acceptance of BLA for MenABCWY in adolescents
- 12/26/22
- Fly Intel: Top five weekend stock stories
- 12/21/22
- Oric Pharmaceuticals to partner with Pfizer on ORIC-533, gets $25M investment
- 12/21/22
- FDA accepts for review Pfizer's NDA for etrasimod
- 12/28/22
- Meta Materials to showcase global technology collaborations at CES 2023
- 12/15/22
- Meta Materials completes distribution of Next Bridge Hydrocarbon shares
- 12/07/22
- Meta Materials says FINRA processed corporate action for exchange of Series A
- 12/06/22
- Meta Materials announces results of Annual Meeting of Shareholders
KALA Kala Pharmaceuticals - 12/27/22
- Kala Pharmaceuticals jumps 64% after FDA accepted application for KPI-012
- 12/27/22
- Kala Pharmaceuticals announces FDA acceptance of IND application for KPI-012
- 11/28/22
- Kala announces submission of IND for KPI-012 for PCED treatment
- 11/01/22
- Kala Pharmaceuticals appoints Farid to board of directors
- $1.04 /
+0.3027 (+41.06%) - 12/08/22
- Jounce Therapeutics presents INNATE Phase 1, SELECT trial data
- 11/10/22
- Jounce Therapeutics expects cash to fund operating expenses into 1Q24
- 11/02/22
- Jounce earns clinical milestone payment under agreement with Gilead
- 12/05/22
- Ideaya Biosciences granted fast track designation for darovasertib
- 11/28/22
- Ideaya Biosciences announces Darrin Beaupre as chief medical officer
- 10/18/22
- Ideaya Biosciences provides update on IDE397 clinical program
- 10/17/22
- Zentalis appoints Lackner as Chief Translational Officer
- 12/07/22
- Generac acquires equity stake in WATT Fuel Cell
- 11/29/22
- Generac falls -4.6%
- 11/09/22
- Generac announces passing of founder Robert Kern
- 10/19/22
- Generac falls -21.9%
- 12/27/22
- Gilead to buy remaining rights for GS-1811 from Jounce Therapeutics for $67M
- 12/22/22
- Kite says Yescarta now approved in Japan for initial treatment
- 12/22/22
- Gilead announces Sunlenca granted FDA approval in multidrug resistant HIV
- 12/20/22
- Kite to acquire Tmunity, terms undisclosed
- 12/28/22
- Voip-Pal.com announces PTAB denies institution of four IPR petitions
- 12/22/22
- Stingray Group launches TV channels on Amazon Freevee, Samsung TV Plus
- 12/20/22
- EU accepts Amazon commitments, ending antitrust investigations
- 12/19/22
- Amazon Web Services awarded $723.88M Navy BPA
- 12/28/22
- AMC Entertainment CEO seeks salary freeze in 2023
- 12/27/22
- AMC Entertainment falls -8.8%
- 12/27/22
- AMC Entertainment falls -7.8%
- 12/23/22
- AMC Entertainment falls -11.2%
- 12/28/22
- Akoustis receives first design win in 5G mobile from Tier-1 RF component company
- 12/21/22
- Akoustis completes qualification of first wafer-level-packages for 5G mobile
- 11/21/22
- Akoustis joins Wi-Fi NOW industry association as Official RF Filter Partner
- 10/26/22
- Akoustis receives three new Wi-Fi 6E design wins
- 12/01/22
- Akili Interactive appoints Scott Kollins as chief medical officer
- 08/26/22
- Temasek Holdings reports 13.5% passive stake in Akili Interactive
- 08/19/22
- Akili to start trading on Nasdaq on August 22
- 12/28/22 Northland
- Generac named a 'top pick for 2023' at Northland
- 12/28/22 Janney Montgomery Scott
- Janney starts Generac with a Buy, sees core HSB headwinds priced in
- 12/28/22 Janney Montgomery Scott
- Generac initiated with a Buy at Janney Montgomery Scott
- 12/20/22 Baird
- Generac downgraded to Neutral from Outperform at Baird
- 12/28/22 Wedbush
- Wedbush lays out what needs to happen for Tesla shares to bottom
- 12/28/22 Baird
- Baird cuts Tesla target to $252, keeps as 'Best Idea' in 2023
- 12/23/22 Wedbush
- Tesla price target lowered to $175 from $250 at Wedbush
- 12/22/22 Canaccord
- Tesla price target lowered to $275 from $304 at Canaccord
- 12/28/22 Cantor Fitzgerald
- Riot, Rivian among Cantor's top technology picks for 2023
- 12/15/22 Northland
- Riot Blockchain price target lowered to $10 from $12 at Northland
- 12/15/22 DA Davidson
- Riot Blockchain price target lowered to $10 from $12 at DA Davidson
- 11/23/22 H.C. Wainwright
- Riot Blockchain assumed with a Buy at H.C. Wainwright
- 12/20/22 Cantor Fitzgerald
- Rivian Automotive initiated with an Overweight at Cantor Fitzgerald
- 12/20/22 Mizuho
- Rivian Automotive price target lowered to $50 from $58 at Mizuho
- 12/13/22 Canaccord
- Rivian Automotive production pause preserves capital, says Canaccord
- 12/28/22 Morgan Stanley
- Akili initiated with an Equal Weight at Morgan Stanley
- 11/18/22 BofA
- Akili Interactive initiated with a Neutral at BofA with spending needed to scale
- 11/18/22 BofA
- Akili Interactive initiated with a Neutral at BofA
- 10/25/22 Credit Suisse
- Akili Interactive initiated with an Outperform at Credit Suisse
- 12/28/22 Capital One
- Capital One starts Ideaya Biosciences at Overweight with $29 price target
- 12/28/22 Capital One
- Ideaya Biosciences initiated with an Overweight at Capital One
- 11/18/22 Baird
- Ideaya Biosciences price target raised to $24 from $18 at Baird
- 10/27/22 Citi
- Ideaya Biosciences initiated with a Buy at Citi
- 12/22/22 Piper Sandler
- Gilead's Sunlenca could expand into broader HIV, says Piper Sandler
- 12/13/22 BofA
- Gilead resumed with a Neutral at BofA
- 12/12/22 Needham
- Arcellx price target raised to $35 from $31 at Needham
- 12/09/22 Piper Sandler
- Gilead price target raised to $104 from $96 at Piper Sandler
- $1.04 /
+0.3027 (+41.06%) - 11/11/22 Raymond James
- Raymond James downgrades Jounce to Outperform on ILT inhibitor data
- 11/10/22 Raymond James
- Jounce Therapeutics downgraded to Outperform from Strong Buy at Raymond James
- 08/30/22 Piper Sandler
- Jounce Therapeutics price target lowered to $6 from $9 at Piper Sandler
- 08/05/22 H.C. Wainwright
- Jounce Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
- 12/19/22 Piper Sandler
- Exxon Mobil price target lowered to $127 from $131 at Piper Sandler
- 11/22/22 Citi
- Exxon Mobil price target raised to $110 from $98 at Citi
- 11/11/22 Piper Sandler
- Exxon Mobil price target raised to $131 from $113 at Piper Sandler
- 11/01/22 Exane BNP Paribas
- Exxon Mobil upgraded to Neutral from Underperform at Exane BNP Paribas
- 12/23/22 Citi
- Sunday Ticket could accelerate adoption of subscriptions at YouTube, says Citi
- 12/19/22 Evercore ISI
- Amazon.com price target lowered to $150 from $170 at Evercore ISI
- 12/16/22 JPMorgan
- JPMorgan cuts Amazon target, says sentiment at multi-year low
- 12/12/22 Wells Fargo
- Amazon GMV beginning to re-accelerate as softlines comps slow, says Wells Fargo
- 12/27/22 Cantor Fitzgerald
- Roivant's upcoming data readouts could move stock higher, says Cantor Fitzgerald
- 12/21/22 Barclays
- Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays
- 12/15/22 Guggenheim
- Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential
- 12/13/22 Piper Sandler
- Takeda deal has positive read through for Ventyx, says Piper
- 11/14/22 Oppenheimer
- Akoustis price target lowered to $7 from $8 at Oppenheimer
- 11/14/22 Piper Sandler
- Akoustis remains on track to continue expanding solutions, says Piper Sandler
- 09/13/22 Piper Sandler
- Akoustis price target lowered to $5 from $7 at Piper Sandler
- 05/17/22 Piper Sandler
- Piper moves to 'more positive stance' on semiconductor stocks
KALA Kala Pharmaceuticals - 11/09/22 Wedbush
- Kala Pharmaceuticals price target raised to $47 from $3 at Wedbush
- 05/24/22 H.C. Wainwright
- Kala Pharmaceuticals price target lowered to $4 from $5 at H.C. Wainwright
- 05/17/22 H.C. Wainwright
- Kala Pharmaceuticals price target lowered to $5 from $6 at H.C. Wainwright
- 03/30/22 Northland
- Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
- 12/28/22 Piper Sandler
- Tilray estimates lowered on softer beer sales at Piper Sandler
- 11/09/22 Bernstein
- Two more states legalize cannabis, $3B added to TAM, says Bernstein
- 11/01/22 Bernstein
- Tilray initiated with Market Perform, $3.90 target at Bernstein
- 11/01/22 Bernstein
- Tilray initiated with a Market Perform at Bernstein
- 11/25/22 Citi
- AMC Entertainment price target lowered to $1.10 from $1.20 at Citi
- 11/06/22 Citi
- AMC Entertainment price target lowered to $1.20 from $3.13 at Citi
- 10/12/22 B. Riley
- AMC Entertainment price target lowered to $7.50 from $11 at B. Riley
- 08/23/22 Wedbush
- Wedbush reiterates Underperform rating on AMC Entertainment, cuts target to $2
- 10/28/22
- Exxon Mobil reports Q3 adjusted EPS $4.45, consensus $3.79
- 10/27/22
- Notable companies reporting before tomorrow's open
- 07/29/22
- Exxon Mobil reports Q2 adjusted EPS $4.14, consensus $3.74
- 10/19/22
- Tesla reports Q3 EPS $1.05, consensus 99c
- 10/19/22
- Notable companies reporting after market close
- 07/20/22
- Tesla reports Q2 EPS $2.27, consensus $1.85
- 07/20/22
- Notable companies reporting after market close
- 10/07/22
- Tilray reports Q1 adjusted EPS (8c) vs. (13c) last year
- 07/28/22
- Tilray reports Q4 EPS (90c) vs. 38c last year
- 11/09/22
- Rivian Automotive reports Q3 adjusted EPS ($1.57), consensus ($1.82)
- 11/09/22
- Notable companies reporting after market close
- 10/27/22
- Amazon reports Q3 EPS 28c with Rivian gain, consensus 21c
- 08/11/22
- Rivian Automotive reports Q2 EPS ($1.89), consensus ($1.67)
- 08/15/22
- Riot Blockchain reports Q2 adjusted EPS (50c), consensus 3c
- 11/01/22
- Pfizer raises FY22 adjusted EPS view to $6.40-$6.50 from $6.30-$6.45
- 11/01/22
- Pfizer reports Q3 adjusted EPS $1.78, consensus $1.39
- 10/31/22
- Notable companies reporting before tomorrow's open
KALA Kala Pharmaceuticals - 11/08/22
- Kala Pharmaceuticals reports Q3 EPS $19.25 vs ($21.41) last year
- 08/11/22
- Kala Pharmaceuticals reports Q2 EPS (38c) vs. (57c) last year
- $1.04 /
+0.3027 (+41.06%) - 11/10/22
- Jounce Therapeutics reports Q3 EPS (60c), consensus (64c)
- 08/04/22
- Jounce Therapeutics reports Q2 EPS (65c), consensus (68c)
- 11/08/22
- Ideaya Biosciences reports Q3 EPS 4c, consensus (62c)
- 08/15/22
- Ideaya Biosciences reports Q2 EPS (57c), consensus (52c)
- 11/02/22
- Generac sees FY22 net revenue growth 22%-24%, consensus $4.7B
- 11/02/22
- Generac reports Q3 adjusted EPS $1.75, consensus $1.83
- 10/19/22
- Generac sees Q3 adjusted EPS $1.75, consensus $3.21
- 08/03/22
- Generac backs FY22 revenue growth view 36%-40%, consensus $5.17B
- 12/20/22
- Gilead expects Tmunity acquisition to reduce FY23 EPS by 18c-22c
- 10/27/22
- Gilead raises FY22 adjusted EPS view to $6.95-$7.15 from $6.35-$6.75
- 10/27/22
- Gilead Sciences reports Q3 adjusted EPS $1.90, consensus $1.43
- 10/27/22
- Notable companies reporting after market close
- 10/27/22
- Amazon sees Q4 revenue $140B-$148B, consensus $155.15B
- 07/28/22
- Amazon reports Q2 AWS net sales $19.73B vs. $14.81B a year ago
- 11/08/22
- AMC Entertainment reports Q3 adjusted EPS (20c), consensus (25c)
- 08/04/22
- AMC Entertainment reports Q2 adjusted EPS (20c), consensus (19c)
- 11/14/22
- Akoustis reports Q4 adjusted EPS (28c), consensus (20c)
- 09/12/22
- Akoustis reports Q4 non-GAAP EPS (26c), consensus (19c)
- 11/10/22
- Akili Interactive reports Q3 net loss ($18.5M) vs ($16.4M) last year
|
Options
|
Notable gainers among… Notable gainers among liquid option names this morning include Tesla (TSLA) $114.53 +5.43, Generac (GNRC) $95.22 +4.06, Bio Techne (TECH) $83.92 +1.71, DexCom (DXCM) $111.53 +1.65, and News Corp. (NWSA) $18.55 +0.27. ShowHide Related Items >><< - 12/27/22
- Cathie Wood's ARK Investment bought 25.1K shares of Tesla today
- 12/27/22
- Tesla debuts Wireless Charging Platform, 'inspired' by Cybertruck design
- 12/27/22
- Tesla down 5% in pre-market following reports of suspended Shanghai output
- 12/22/22
- Tesla up 2% afterhours as CEO Musk says he will pause his share sales
- 12/01/22
- Bio-Techne, Oxford Nanopore announce collaboration
- 11/15/22
- Bio-Techne opens new immunoassay manufacturing facility
- 10/12/22
- Bio-Techne announces introduction of new vivid fluorescent dyes
- 10/11/22
- Bio-Techne introduces new Simple Plex AAV viral titer assays
- 12/06/22
- Fox Corp. provides update on potential News Corp. transaction
- 11/08/22
- News Corp. says Special Committee has not decided on pursuit of Fox deal
- 11/01/22
- Fox Corp.: Special Committee has not made any determination on News Corp.
- 10/14/22
- Fox Corp. forms committee to begin exploring potential News Corp. combination
- 12/07/22
- Generac acquires equity stake in WATT Fuel Cell
- 11/29/22
- Generac falls -4.6%
- 11/09/22
- Generac announces passing of founder Robert Kern
- 10/19/22
- Generac falls -21.9%
- 10/04/22
- DexCom announces Dexcom G7 CGM availability in five new countries
- 08/31/22
- DexCom promotes Jake Leach to COO
- 08/01/22
- DexCom announces availability of real-time glucose monitoring in diabetes
- 07/28/22
- DexCom drops 17% after Q2 results, FY22 guidance miss estimates
- 12/28/22 Wedbush
- Wedbush lays out what needs to happen for Tesla shares to bottom
- 12/28/22 Baird
- Baird cuts Tesla target to $252, keeps as 'Best Idea' in 2023
- 12/23/22 Wedbush
- Tesla price target lowered to $175 from $250 at Wedbush
- 12/22/22 Canaccord
- Tesla price target lowered to $275 from $304 at Canaccord
- 12/28/22 Northland
- Generac named a 'top pick for 2023' at Northland
- 12/28/22 Janney Montgomery Scott
- Janney starts Generac with a Buy, sees core HSB headwinds priced in
- 12/28/22 Janney Montgomery Scott
- Generac initiated with a Buy at Janney Montgomery Scott
- 12/20/22 Baird
- Generac downgraded to Neutral from Outperform at Baird
- 12/13/22 Deutsche Bank
- Bio-Techne initiated with a Buy at Deutsche Bank
- 12/12/22 Citi
- Bio-Techne upgraded to Buy from Neutral at Citi
- 12/12/22 Citi
- Bio-Techne upgraded to Buy from Neutral at Citi
- 12/06/22 RBC Capital
- Bio-Techne initiated with a Sector Perform at RBC Capital
- 12/20/22 Stifel
- DexCom price target raised to $130 from $120 at Stifel
- 12/12/22 Citi
- DexCom price target raised to $146 from $117 at Citi
- 10/28/22 Cowen
- DexCom price target raised to $114 from $85 at Cowen
- 10/28/22 Citi
- DexCom price target raised to $117 from $105 at Citi
- 10/17/22 Morgan Stanley
- Morgan Stanley says Fox-News combo would balance more scale with more complexity
- 10/17/22 Loop Capital
- News Corp. downgraded to Hold from Buy at Loop Capital
- 10/17/22 Credit Suisse
- Fox Corp. downgraded to Neutral from Outperform at Credit Suisse
- 07/28/22 Macquarie
- News Corp. downgraded to Neutral at Macquarie ahead of expected 'soft' report
- 10/19/22
- Tesla reports Q3 EPS $1.05, consensus 99c
- 10/19/22
- Notable companies reporting after market close
- 07/20/22
- Tesla reports Q2 EPS $2.27, consensus $1.85
- 07/20/22
- Notable companies reporting after market close
- 11/01/22
- Bio-Techne reports Q1 adjusted EPS $1.78, consensus $1.83
- 08/04/22
- Bio-Techne reports Q4 adjusted EPS $2.05 vs. $1.88 last year
- 11/08/22
- News Corp. reports Q1 adjusted EPS 12c, consensus 15c
- 08/08/22
- News Corp. reports Q4 adjusted EPS 37c, consensus 7c
- 11/02/22
- Generac sees FY22 net revenue growth 22%-24%, consensus $4.7B
- 11/02/22
- Generac reports Q3 adjusted EPS $1.75, consensus $1.83
- 10/19/22
- Generac sees Q3 adjusted EPS $1.75, consensus $3.21
- 08/03/22
- Generac backs FY22 revenue growth view 36%-40%, consensus $5.17B
- 10/27/22
- DexCom narrows FY22 revenue view to $2.88B-$2.91B from $2.86B-$2.91B
- 10/27/22
- DexCom reports Q3 adjusted EPS 28c, consensus 24c
- 10/27/22
- Notable companies reporting after market close
- 07/28/22
- DexCom sees FY22 revenue $2.86B-$2.91B, consensus $2.92B
- 12/27/22
- Tesla tells Global Times report on Shanghai plant suspension 'inaccurate'
- 12/23/22
- Wyden seeks information from carmakers on Chinese supply chains, CNBC reports
- 12/22/22
- Tesla's Musk says will not sell more shares for another two years, Reuters says
- 12/22/22
- NHTSA investigates Thanksgiving Day pileup involving Tesla, AP reports
- 12/23/22
- Michael Bloomberg eyeing Dow Jones, Washington Post, Axios reports
- 10/14/22
- Rupert Murdoch mulls recombining Fox Corp., News Corp., WSJ reports
- 09/24/22
- More power outages make 'storm stock' Generac a Buy, Barron's says
- 12/28/22
- Fly Intel: Pre-market Movers
- 12/27/22
- What You Missed On Wall Street On Tuesday
- 12/27/22
- What You Missed On Wall Street This Morning
- 12/27/22
- What You Missed This Week in EVs and Clean Energy
- 12/23/22
- What You Missed On Wall Street On Friday
- 12/23/22
- What You Missed On Wall Street This Morning
- 12/23/22
- Fly Intel: Pre-market Movers
- 12/06/22
- What You Missed On Wall Street On Tuesday
- 11/29/22
- What You Missed On Wall Street On Tuesday
- 11/29/22
- What You Missed On Wall Street This Morning
- 11/25/22
- What You Missed On Wall Street On Friday
- 10/28/22
- What You Missed On Wall Street On Friday
- 10/28/22
- What You Missed On Wall Street This Morning
- 10/27/22
- Fly Intel: After-Hours Movers
- 10/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/28/22
- Notable open interest changes for December 28th
- 12/28/22
- Tesla put buyer realizes 46% same-day gains
- 12/27/22
- Notable open interest changes for December 27th
- 12/23/22
- Notable open interest changes for December 23rd
- 12/19/22
- Generac call volume above normal and directionally bullish
- 12/16/22
- Early notable gainers among liquid option names on December 16th
- 11/09/22
- Generac put volume heavy and directionally bearish
- 10/14/22
- Generac put volume heavy and directionally bearish
- 10/28/22
- Early notable gainers among liquid option names on October 28th
- 10/27/22
- DexCom options imply 6.2% move in share price post-earnings
- 10/07/22
- Early notable gainers among liquid option names on October 7th
- 08/01/22
- Early notable gainers among liquid option names on August 1st
|
On The Fly
|
Check out this morning's… ShowHide Related Items >><< - 08/03/22
- Minerva Surgical announces Time to Talk campaign
- 07/21/22
- Minerva Surgical appoints Sung to board of directors
- $109.05 /
-14.09 (-11.44%) - 12/27/22
- Cathie Wood's ARK Investment bought 25.1K shares of Tesla today
- 12/27/22
- Tesla debuts Wireless Charging Platform, 'inspired' by Cybertruck design
- 12/27/22
- Tesla down 5% in pre-market following reports of suspended Shanghai output
- 12/22/22
- Tesla up 2% afterhours as CEO Musk says he will pause his share sales
- 12/28/22
- Pixelworks announces strategic equity investment in Shanghai subsidiary
- 11/21/22
- Pixelworks expands collaboration with MediaTek
- 08/18/22
- Pixelworks makes strategic investment in Shanghai subsidiary
- 12/27/22
- Southwest sees flying roughly one third of schedule for 'next several days'
- 12/27/22
- Southwest says it continues 'recovering from operational challenges'
- 12/27/22
- U.S. Department of Transportation to examine Southwest cancellations
- 12/16/22
- Southwest customer service employees approve new five-year contract
KALA Kala Pharmaceuticals - 12/27/22
- Kala Pharmaceuticals jumps 64% after FDA accepted application for KPI-012
- 12/27/22
- Kala Pharmaceuticals announces FDA acceptance of IND application for KPI-012
- 11/28/22
- Kala announces submission of IND for KPI-012 for PCED treatment
- 11/01/22
- Kala Pharmaceuticals appoints Farid to board of directors
- 12/27/22
- Gilead to buy remaining rights for GS-1811 from Jounce Therapeutics for $67M
- 12/08/22
- Jounce Therapeutics presents INNATE Phase 1, SELECT trial data
- 11/10/22
- Jounce Therapeutics expects cash to fund operating expenses into 1Q24
- 11/02/22
- Jounce earns clinical milestone payment under agreement with Gilead
- 12/07/22
- Generac acquires equity stake in WATT Fuel Cell
- 11/29/22
- Generac falls -4.6%
- 11/09/22
- Generac announces passing of founder Robert Kern
- 10/19/22
- Generac falls -21.9%
- 12/22/22
- Kite says Yescarta now approved in Japan for initial treatment
- 12/22/22
- Gilead announces Sunlenca granted FDA approval in multidrug resistant HIV
- 12/20/22
- Kite to acquire Tmunity, terms undisclosed
- 11/11/22 Raymond James
- Raymond James downgrades Jounce to Outperform on ILT inhibitor data
- 11/10/22 Raymond James
- Jounce Therapeutics downgraded to Outperform from Strong Buy at Raymond James
- 08/30/22 Piper Sandler
- Jounce Therapeutics price target lowered to $6 from $9 at Piper Sandler
- 08/05/22 H.C. Wainwright
- Jounce Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
KALA Kala Pharmaceuticals - 11/09/22 Wedbush
- Kala Pharmaceuticals price target raised to $47 from $3 at Wedbush
- 05/24/22 H.C. Wainwright
- Kala Pharmaceuticals price target lowered to $4 from $5 at H.C. Wainwright
- 05/17/22 H.C. Wainwright
- Kala Pharmaceuticals price target lowered to $5 from $6 at H.C. Wainwright
- 03/30/22 Northland
- Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
- 01/18/22 Colliers
- Pixelworks upgraded to Buy from Neutral at Colliers
- 12/28/22 Northland
- Generac named a 'top pick for 2023' at Northland
- 12/28/22 Janney Montgomery Scott
- Janney starts Generac with a Buy, sees core HSB headwinds priced in
- 12/28/22 Janney Montgomery Scott
- Generac initiated with a Buy at Janney Montgomery Scott
- 12/20/22 Baird
- Generac downgraded to Neutral from Outperform at Baird
- $109.05 /
-14.09 (-11.44%) - 12/28/22 Wedbush
- Wedbush lays out what needs to happen for Tesla shares to bottom
- 12/28/22 Baird
- Baird cuts Tesla target to $252, keeps as 'Best Idea' in 2023
- 12/23/22 Wedbush
- Tesla price target lowered to $175 from $250 at Wedbush
- 12/22/22 Canaccord
- Tesla price target lowered to $275 from $304 at Canaccord
- 10/12/22 Piper Sandler
- CMS proposal a positive for Med Tech sector, says Piper Sandler
- 08/10/22 JPMorgan
- Minerva Surgical downgraded to Underweight from Overweight at JPMorgan
- 08/09/22 Piper Sandler
- Minerva Surgical price target lowered to $5 from $6 at Piper Sandler
- 05/12/22 Piper Sandler
- Minerva Surgical price target lowered to $6 from $12 at Piper Sandler
- 12/16/22 Goldman Sachs
- Southwest resumed with a Neutral at Goldman Sachs
- 12/15/22 Cowen
- Copa Holdings upgraded to Outperform at Cowen amid airlines rating shake-up
- 12/08/22 Susquehanna
- Southwest guidance suggests risk around order book, says Susquehanna
- 12/08/22 Deutsche Bank
- Southwest price target raised to $62 from $60 at Deutsche Bank
- 12/22/22 Piper Sandler
- Gilead's Sunlenca could expand into broader HIV, says Piper Sandler
- 12/13/22 BofA
- Gilead resumed with a Neutral at BofA
- 12/12/22 Needham
- Arcellx price target raised to $35 from $31 at Needham
- 12/09/22 Piper Sandler
- Gilead price target raised to $104 from $96 at Piper Sandler
- 08/09/22
- Minerva Surgical reports Q2 EPS (20c), two estimates (34c)
- $109.05 /
-14.09 (-11.44%) - 10/19/22
- Tesla reports Q3 EPS $1.05, consensus 99c
- 10/19/22
- Notable companies reporting after market close
- 07/20/22
- Tesla reports Q2 EPS $2.27, consensus $1.85
- 07/20/22
- Notable companies reporting after market close
- 12/28/22
- Pixelworks reaffirms Q4 revenue guidance of $16M-$18M, consensus $17M
- 11/07/22
- Pixelworks sees Q4 EPS (4c) to 1c, consensus (5c)
- 11/07/22
- Pixelworks reports Q3 adjusted EPS (6c), consensus (6c)
- 08/10/22
- Pixelworks sees Q3 adjusted EPS (9c)-(5c)
- 10/27/22
- Southwest sees FY22 ASMs down 4.5%
- 10/27/22
- Southwest sees Q4 revenue up 13%-17%, consensus $6.23B
- 10/27/22
- Southwest reports Q3 adjusted EPS 50c, consensus 42c
- 10/26/22
- Notable companies reporting before tomorrow's open
KALA Kala Pharmaceuticals - 11/08/22
- Kala Pharmaceuticals reports Q3 EPS $19.25 vs ($21.41) last year
- 08/11/22
- Kala Pharmaceuticals reports Q2 EPS (38c) vs. (57c) last year
- 11/10/22
- Jounce Therapeutics reports Q3 EPS (60c), consensus (64c)
- 08/04/22
- Jounce Therapeutics reports Q2 EPS (65c), consensus (68c)
- 11/02/22
- Generac sees FY22 net revenue growth 22%-24%, consensus $4.7B
- 11/02/22
- Generac reports Q3 adjusted EPS $1.75, consensus $1.83
- 10/19/22
- Generac sees Q3 adjusted EPS $1.75, consensus $3.21
- 08/03/22
- Generac backs FY22 revenue growth view 36%-40%, consensus $5.17B
- 12/20/22
- Gilead expects Tmunity acquisition to reduce FY23 EPS by 18c-22c
- 10/27/22
- Gilead raises FY22 adjusted EPS view to $6.95-$7.15 from $6.35-$6.75
- 10/27/22
- Gilead Sciences reports Q3 adjusted EPS $1.90, consensus $1.43
- 10/27/22
- Notable companies reporting after market close
- $109.05 /
-14.09 (-11.44%) - 12/27/22
- Tesla tells Global Times report on Shanghai plant suspension 'inaccurate'
- 12/23/22
- Wyden seeks information from carmakers on Chinese supply chains, CNBC reports
- 12/22/22
- Tesla's Musk says will not sell more shares for another two years, Reuters says
- 12/22/22
- NHTSA investigates Thanksgiving Day pileup involving Tesla, AP reports
- 12/27/22
- Southwest to operate just over one-third of typical schedule, WSJ reports
- 12/26/22
- Southwest's troubles mount with cancellations, WSJ reports
- 11/21/22
- Appeals court rejects class action suits against Boeing, Southwest, Reuters says
- 11/20/22
- Airlines push for lone pilot flights to cut costs, Bloomberg reports
- 09/24/22
- More power outages make 'storm stock' Generac a Buy, Barron's says
- $109.05 /
-14.09 (-11.44%) - 12/27/22
- What You Missed On Wall Street On Tuesday
- 12/27/22
- What You Missed On Wall Street This Morning
- 12/27/22
- What You Missed This Week in EVs and Clean Energy
- 12/27/22
- Fly Intel: Pre-market Movers
- 10/27/22
- Fly Intel: Pre-market Movers
KALA Kala Pharmaceuticals - 12/01/22
- Biotech Alert: Searches spiking for these stocks today
- 11/28/22
- Fly Intel: After-Hours Movers
- 11/11/22
- Biotech Alert: Searches spiking for these stocks today
- 12/27/22
- After-Hours Movers
- 11/11/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/29/22
- What You Missed On Wall Street On Tuesday
- 11/29/22
- What You Missed On Wall Street This Morning
- 11/25/22
- What You Missed On Wall Street On Friday
- 10/22/22
- Buy/Sell: Wall Street's top 10 stock calls this week
- 12/20/22
- What You Missed On Wall Street On Tuesday
- 12/20/22
- What You Missed On Wall Street This Morning
- 12/09/22
- What You Missed On Wall Street This Morning
- 11/30/22
- Biotech Alert: Searches spiking for these stocks today
- $109.05 /
-14.09 (-11.44%) - 12/28/22
- Notable open interest changes for December 28th
- 12/28/22
- Tesla put buyer realizes 46% same-day gains
- 12/27/22
- Notable open interest changes for December 27th
- 12/23/22
- Notable open interest changes for December 23rd
- 12/27/22
- Unusually active option classes on open December 27th
- 12/05/22
- Southwest call volume above normal and directionally bullish
- 10/27/22
- Unusually active option classes on open October 27th
- 07/28/22
- Unusually active option classes on open July 28th
- 12/19/22
- Generac call volume above normal and directionally bullish
- 12/16/22
- Early notable gainers among liquid option names on December 16th
- 11/09/22
- Generac put volume heavy and directionally bearish
- 10/14/22
- Generac put volume heavy and directionally bearish
- 11/02/22
- Unusually active option classes on open November 2nd
- 10/28/22
- Early notable gainers among liquid option names on October 28th
- 10/27/22
- Gilead options imply 2.6% move in share price post-earnings
- 09/30/22
- Unusually active option classes on open September 30th
|
Recommendations
|
Northland analyst Donovan… Northland analyst Donovan Schafer selected Generac as a "top pick for 2023," citing his belief that the market is overlooking recent outage events that should drive home standby, or "HSB," generator demand while being "distracted by the near-term installation bottlenecks that obscure the underlying reality" that he expects to become clearer as 2023 unfolds. Hurricane Ian, the 1.5M in outages two days before Christmas, an outage-causing earthquake, and two terror attacks, are all recent events that highlight "grid vulnerability," said Schafer, who keeps an Outperform rating and $180 price target on Generac shares. ShowHide Related Items >><< - 12/07/22
- Generac acquires equity stake in WATT Fuel Cell
- 11/29/22
- Generac falls -4.6%
- 11/09/22
- Generac announces passing of founder Robert Kern
- 10/19/22
- Generac falls -21.9%
- 12/28/22 Janney Montgomery Scott
- Janney starts Generac with a Buy, sees core HSB headwinds priced in
- 12/28/22 Janney Montgomery Scott
- Generac initiated with a Buy at Janney Montgomery Scott
- 12/20/22 Baird
- Generac downgraded to Neutral from Outperform at Baird
- 12/13/22 Stifel
- Generac transferred with a Hold, price target lowered to $98 at Stifel
- 11/02/22
- Generac sees FY22 net revenue growth 22%-24%, consensus $4.7B
- 11/02/22
- Generac reports Q3 adjusted EPS $1.75, consensus $1.83
- 10/19/22
- Generac sees Q3 adjusted EPS $1.75, consensus $3.21
- 08/03/22
- Generac backs FY22 revenue growth view 36%-40%, consensus $5.17B
- 09/24/22
- More power outages make 'storm stock' Generac a Buy, Barron's says
- 11/29/22
- What You Missed On Wall Street On Tuesday
- 11/29/22
- What You Missed On Wall Street This Morning
- 11/25/22
- What You Missed On Wall Street On Friday
- 10/22/22
- Buy/Sell: Wall Street's top 10 stock calls this week
- 12/19/22
- Generac call volume above normal and directionally bullish
- 12/16/22
- Early notable gainers among liquid option names on December 16th
- 11/09/22
- Generac put volume heavy and directionally bearish
- 10/14/22
- Generac put volume heavy and directionally bearish
|
Initiation
|
As previously reported,… As previously reported, Janney Montgomery Scott analyst Sean Milligan initiated coverage of Generac with a Buy rating and $160 fair value estimate. The core residential home standby, or "HSB," generator business is in the early stages of a downturn, but with shares down about 80% from their peak Milligan feels this "has already been discounted in the share price," he tells investors. The shares now trading at a discount to industrial peers presents a "free option" on clean energy growth, argues Milligan, who also sees consistent free cash flow generation and buyback potential providing potential support for the stock and balancing out near-term concerns for residential HSB market trends. ShowHide Related Items >><< - 12/07/22
- Generac acquires equity stake in WATT Fuel Cell
- 11/29/22
- Generac falls -4.6%
- 11/09/22
- Generac announces passing of founder Robert Kern
- 10/19/22
- Generac falls -21.9%
- 12/28/22 Janney Montgomery Scott
- Generac initiated with a Buy at Janney Montgomery Scott
- 12/20/22 Baird
- Generac downgraded to Neutral from Outperform at Baird
- 12/13/22 Stifel
- Generac transferred with a Hold, price target lowered to $98 at Stifel
- 12/08/22 Oppenheimer
- Generac price target lowered to $115 from $135 at Oppenheimer
- 11/02/22
- Generac sees FY22 net revenue growth 22%-24%, consensus $4.7B
- 11/02/22
- Generac reports Q3 adjusted EPS $1.75, consensus $1.83
- 10/19/22
- Generac sees Q3 adjusted EPS $1.75, consensus $3.21
- 08/03/22
- Generac backs FY22 revenue growth view 36%-40%, consensus $5.17B
- 09/24/22
- More power outages make 'storm stock' Generac a Buy, Barron's says
- 11/29/22
- What You Missed On Wall Street On Tuesday
- 11/29/22
- What You Missed On Wall Street This Morning
- 11/25/22
- What You Missed On Wall Street On Friday
- 10/22/22
- Buy/Sell: Wall Street's top 10 stock calls this week
- 12/19/22
- Generac call volume above normal and directionally bullish
- 12/16/22
- Early notable gainers among liquid option names on December 16th
- 11/09/22
- Generac put volume heavy and directionally bearish
- 10/14/22
- Generac put volume heavy and directionally bearish
|